Conservative Group Claims Mail-Order Abortion Policy Drives 500 Daily Procedures

A conservative advocacy organization has released findings suggesting that regulatory changes implemented during the previous administration continue to facilitate widespread access to abortion medications through remote healthcare services, according to a report obtained by local media outlets.

The Restoration of America Foundation, a group that opposes abortion rights, claims in its analysis that federal drug agency policies allowing abortion pills to be prescribed via telehealth and delivered by mail are reportedly driving more than 500 such procedures daily. The organization cites data from research institutes that track reproductive healthcare trends.

According to the report, chemical abortions now allegedly account for approximately 63% of all abortion procedures in the nation as of 2023, representing a significant increase from 39% in 2017. Observers note this shift reflects broader changes in how reproductive healthcare is accessed across the country.

The advocacy group estimates there were roughly 170,000 additional abortions in 2024 compared to what would have occurred if rates had remained at 2019 levels, before the regulatory changes were implemented. The organization attributes this increase primarily to what it characterizes as relaxed oversight of abortion medications.

“Since hitting a low in 2017, the national abortion rate has seen a persistent and troubling climb,” the report states, noting that overall procedures reportedly grew by 22% between 2019 and 2024 while the nation’s population increased by only 2.9% during the same period.

The findings suggest that mail-order abortion procedures comprised roughly one in four such procedures in the country during the first half of the current year. Data cited in the report indicates an estimated 244,590 remote consultations facilitated abortion access in 2024, including more than 120,000 medications sent to regions where such procedures face legal restrictions following the highest court’s decision to return regulatory authority to individual states.

The previous administration’s drug agency removed requirements that women consult physicians in person before being prescribed mifepristone, instead allowing remote consultations and mail delivery. Critics argue that federal regulators justified these changes using what they characterize as limited safety studies, particularly after mandatory reporting requirements for complications were reportedly reduced under an earlier administration.

Doug Truax, the chief executive of the advocacy organization, told media outlets that the current system allows individuals to “call up and say whatever they need to say to get the drug in the mail.” He claims abortion numbers have risen dramatically, from 874,000 in 2023 to an estimated 1.1 million in 2024, and projects continued increases under current policies.

“There’s about 150 women a day that are being seriously harmed by this drug,” Truax allegedly stated, citing concerns about medical complications when patients don’t receive in-person examinations. “We need to get them to go see the doctor,” he reportedly added, referencing potential risks including ectopic pregnancies and other complications.

The organization frames its concerns as addressing both opposition to abortion procedures and what it characterizes as women’s health and safety issues. Truax noted that states with larger populations are reportedly receiving the most abortion medications through mail delivery, while some state governments have enacted protective legislation preventing legal action against providers.

“For instance, [a southern state], they don’t have abortion anymore, but they sure do,” he reportedly said, suggesting that mail-order access undermines state-level restrictions. “People think it’s down to zero. It’s not at all.”

The federal drug agency continues to maintain the suspension of in-person dispensing requirements for mifepristone, a safety measure that had reportedly been in place for approximately 20 years before being permanently removed following temporary COVID-era changes.

This policy faced legal challenges under the previous administration, though the nation’s highest court allowed it to remain in effect after ruling that challengers lacked proper legal standing. A regional appeals court had previously determined that the drug agency’s actions were likely “arbitrary and capricious” under administrative law.

Truax urged the current administration to reverse the policy, suggesting federal authorities have the power to reinstate previous requirements. “I think that from a political standpoint, they’d rather not talk about it,” he reportedly said, while arguing that conservative supporters may become concerned if abortion numbers continue rising.

Lawmakers from the conservative faction and state officials have reportedly been pressing the new administration to take action on the issue. More than 20 state attorneys general previously urged the current health secretary and drug agency commissioner to conduct a safety review of mifepristone and consider reinstating previous safeguards.

The health secretary and drug agency head have reportedly committed to reviewing the medication’s safety profile, though no timeline has been announced for releasing their findings. The advocacy organization’s report concludes that federal authorities “already have the tools at their disposal” to reverse previous policy changes and restore what it characterizes as “commonsense medical safeguards.”